Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Sep

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Matthew Seymour, MD: A Clinical Trialist’s Perspective

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions

Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care

Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain

Cervical Cancer Nonscreening Increased Over Nearly 2 Decades